University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA
Michael Thomas Schweizer , Emmanuel S. Antonarakis , Mario A. Eisenberger , Peter Nelson , Jun Luo , Colin Pritchard , Samuel R. Denmeade
Background: BAT is a promising treatment for CRPC and preclinical work has shown that its effects may be mediated by inducing DNA damage or cell cycle arrest. We sought to evaluate if mutations in DNA damage repair (DDR) genes or cell cycle regulators were associated with improved outcomes. Methods: Biospecimens from CRPC patients enrolled to studies testing BAT underwent germline or somatic next-generation sequencing (NGS). Samples tested included plasma (i.e. cell-free DNA) (N = 79), tumor tissue (N = 21) and saliva (N = 10). A variety of clinical grade NGS platforms were generally used. Given the concern for false negatives, we excluded cases if plasma NGS did not reveal a somatic alteration. Absence of a germline alteration was not assumed to indicate absence of somatic alterations. Comparative analyses to assess candidate biomarkers of BAT efficacy were performed. Results: Most patients received BAT following one or more next generation hormonal therapy, while 6 received BAT as first-line CRPC therapy. Of 65 cases where a germline or somatic pathogenic alteration in any gene was detected, 30 (46%) had evidence of homologous recombination deficiency (HRD), with mutations found in BRCA2 (N = 10), ATM (N = 8), CHEK2 (N = 5), PALB2 (N = 4), CDK12 (N = 3), CHD1 (N = 2), FANCA (N = 1), FANCD2 (N = 1) and BRCA1 (N = 1). TP53 alterations were also common (27/65; 42%). HRD mutations associated with increased PSA50 responses, with a trend toward improved PSA50 responses in TP53 mutated cases too (Table). In a combined analysis, men with HRD and/or TP53 mutations had improved PSA50 responses and near-significant improvement in progression free survival (PFS). Conclusions: These preliminary data suggest that BAT may be most efficacious in cancers harboring mutations in genes involved in DDR and/or cell cycle regulation. These results require prospective confirmation.
Biomarker panel | PSA50 response rate | P-value | Median PFS, mo | Hazard Ratio (95% CI) | ||||
---|---|---|---|---|---|---|---|---|
HRD | 14/30 (47%) | 0.02 | 5.48 | 0.90 (0.53 - 1.52, P = 0.69) | ||||
No HRD | 6/32 (19%) | 5.34 | ||||||
TP53 mutation | 11/27 (41%) | 0.12 | 5.38 | 0.70 (0.40 - 1.22, P = 0.21) | ||||
No TP53 mutation | 7/32 (22%) | 5.44 | ||||||
HRD and/or TP53 mutation | 20/47 (43%) | 0.008 | 5.51 | 0.59 (0.33 - 1.08, P = 0.087) | ||||
No HRD or TP53 mutation | 1/16 (6.3%) | 4.62 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: Jonathan Poh
2024 ASCO Annual Meeting
First Author: Ted Van Alstyne
2022 ASCO Annual Meeting
First Author: Jianhua Liu
2023 ASCO Annual Meeting
First Author: Kwangrok Jung